Treatment, Medication & Supplement Directory

A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.

Directory explains “what it is.”Guides explain how owners can discuss, use, monitor, or prepare for a treatment option with veterinary guidance.

6 entriesShowing 1–6

Veterinarian reviewing a molecular target concept and an unbranded oral medicine with a dog caregiver

Prescription Drug · Targeted Therapy · Dogs & Cats · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy · Published Study

Tyrosine Kinase Inhibitors: A Class-Level Monitoring Framework

Tyrosine kinase inhibitors are not one interchangeable drug class; target profile, label, evidence, dosing, monitoring, and adverse effects differ by product and patient.

Prescription Drug · Targeted Therapy · Dogs · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy · Limited / Emerging Evidence

Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review

Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.

Named profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.

Prescription Drug · Targeted Therapy · Masivet · Dogs · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy

Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors

Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.

Veterinarian reviewing an immune pathway concept and an unbranded biologic treatment with a dog caregiver

Named profile Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic BiologicRepresentative category illustration – no product packaging is shown.

Immunotherapy · Oncept · Dogs · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy · Manufacturer Information

Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic Biologic

Oncept is a USDA-listed canine melanoma DNA biologic; license status, specialist access, intended setting, evidence limitations, and cost require current review.

Veterinary team and caregiver discussing a shared care plan for a dog

Monitoring / Diagnostic · Palliative Care Plan · Dogs & Cats · Before Chemotherapy · Before Surgery · Before Targeted Therapy · New Diagnosis

Multidisciplinary Tumor Board and Coordinated Case Review

A coordinated case review can align pathology, imaging, surgery, medical oncology, radiation oncology, primary care, and supportive-care perspectives around one patient-specific decision. It is a consultation process, not…

Monitoring / Diagnostic · Dogs & Cats · Before Chemotherapy · Before Targeted Therapy · Long-term Management · New Diagnosis · Limited / Emerging Evidence

Veterinary Cancer Clinical Trials: Eligibility, Consent, and Alternatives

A clinical trial may offer structured access to an investigational strategy or answer an important research question, but listing, enrollment, or novelty does not mean the study is…